Gilberto Jimenez, MD
Internal Medicine · Hialeah, FLNPI 1083690366
Payments from drug & device makers
What this record shows
UCB GmbH accounts for 63.1% of it on its own, with 7 other manufacturers making up the rest. Reporting peaked in 2020 at $1,378 and has fallen 91.7% since, to $114 in 2025.
Across 21 payments — averaging $102.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- UCB GmbH$1K
- Modernatx, Inc.$413
- Novartis$123
- Kowa Pharmaceuticals America, Inc.$114
- AstraZeneca$58
- Smith+Nephew$57
- plus $32 from 2 others
Across 510 payments — averaging $69,738 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Modernatx, Inc.$32.2M
- Organon$2.7M
- BD$527K
- Pfizer$130K
- Chiesi USA, Inc.$22K
- LEO Pharma AS$2K
- plus $346 from 2 others
What the payments were for
- Travel & lodging$1,27259%
- Food & beverage$89041%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| UCB GmbH | 9 | $1,364 |
| Modernatx, Inc. | 2 | $413 |
| Novartis | 1 | $123 |
| Kowa Pharmaceuticals America, Inc. | 1 | $114 |
| AstraZeneca | 4 | $58 |
| Smith+Nephew | 2 | $57 |
| Amarin Pharma, Inc. | 1 | $17 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,162 in reported general payments places this provider in the 80th percentile of 8,530 internal medicine providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 48 | $33,626 |
| MounjaroTirzepatide | 32 | $31,784 |
| TrulicityDulaglutide | 34 | $30,199 |
| LinzessLinaclotide | 32 | $16,806 |
| TradjentaLinagliptin | 24 | $16,800 |
| OzempicSemaglutide | 16 | $13,735 |
| JanumetSitagliptin Phos/Metformin Hcl | 21 | $10,489 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 30 | $7,411 |
| Lidocaine | 28 | $6,680 |
| Diclofenac Sodium | 106 | $5,774 |
| Brinzolamide | 25 | $4,959 |
| EdarbyclorAzilsartan Med/Chlorthalidone | 13 | $2,804 |
| Potassium Chloride | 30 | $2,482 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 16 | $2,264 |
| Clobetasol Propionate | 13 | $2,004 |
Paid to pharmacies, not to this prescriber.
Other internal medicine in Hialeah
- Haytham ElgammalMiami$2.2M
- Keith RubinFort Lauderdale$2M
- Michael SensionFort Lauderdale$1M
- Quang NguyenOcala$434K
- Luis Correa LunaSanford$412K
- Michael OleksykFort Myers$365K
- Andrew KuykendallTampa$322K
- Howard FederoffCoconut Grove$302K
- Bianka EperjesiovaGainesville$260K
- Julio ConradoFort Myers$247K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.